Assessment of antineutrophil-cytoplasmic autoantibodies (ANCA) in type 1 diabetic patients;Ocena wystȩpowania przeciwciał przeciwko cytoplazmie granulocytów obojȩtnochłonnych (ANCA) u chorych na cukrzycȩ typu 1

Polskie Archiwum Medycyny Wewnetrznej

Volumn 113, Issue 6, 2005, Pages 552-556

  Schlaffke, Judyta ^a   Zozulińska, Dorota ^a   Wierusz Wysocka, Bogna ^a  

^a Katedra i Klinika Chorób Wewn trznych i Diabetologii UM im Karola Marcinkowskiego w Poznaniu Szpital Miejski im Franciszka Raszei   (Poland)

Author keywords

Antineutrophil cytoplasmic autoantibodies; Diabetic microangiopathy; Type 1 diabetes mellitus

Indexed keywords

C REACTIVE PROTEIN; ENZYME ANTIBODY; HEMOGLOBIN A1C; MYELOPEROXIDASE ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROTEINASE 3 ANTIBODY; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

ADULT; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETIC MICROANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPOTHESIS; IMMUNOFLUORESCENCE; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; PARAMETERS OF MEASUREMENT AND ANALYSIS; PATHOGENESIS; PROTEIN ANALYSIS; RISK; RISK ASSESSMENT; SEX DIFFERENCE; BLOOD; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; MIDDLE AGED; NONPARAMETRIC TEST; VASCULITIS;

ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CONFIDENCE INTERVALS; DIABETES MELLITUS, TYPE 1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; ODDS RATIO; STATISTICS, NONPARAMETRIC; VASCULITIS;

EID: 27144514949     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Cohen R.A.: Dysfunction of vascular endothelium in diabetes mellitus. Circulation, 1993, 87, V67.
2. Schmid-Schönbein G.W.: The damaging potential of leukocyte activation in the microcirculation. Angiology, 1993, 44, 45.
3. Adams D.H., Shaw S.: Leukocyte-endothelial interactions and regulation of leukocyte migration. Lancet, 1994, 343, 831.
4. Morigi M., Angioletti S., Imberti B. i wsp.: Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycaemia in a NF-kB-dependent fashion. J. Clin. Invest., 1998, 101, 1905.
5. Zozulińska D., Wierusz-Wysocka B.: Wybrane mechanizmy patogenetyczne przewlekłych powikłań cukrzycy: Rola granulocytów obojȩtnochłonnych. Diabetologia Polska, 2000, 7, 198.
6. Hagen E.C., Andrassy K., Csernok E. i wsp.: Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA) - A report on the second phase of an international cooperative study on the standardization of ANCA assays. J. Immunol. Method., 1996, 196, 1.
7. Davies D.J., Moran J.E. Niall J.F. i wsp.: Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br. Med. J., 982, 265, 606.
8. Villalta D., Tonutti E., Tampoia M. i wsp.: Analytical and diagnostic accuracy of the ELiA automatem enzyme fluoroimmunoassay for antineutrophil cytoplasmic autoantibody detection. Clin. Chem Lab. Med., 2004, 42, 1161.
9. Cielecka-Kuszyk J., Woźniak M., Pawłowska J. i wsp.: Znaczenie diagnostyczne przeciwciał przeciwgranulocytarnych cytoplazmatycznych w schorzeniach autoimmunologicznych ze szczególnym uwzglȩdnieniem chorób wa̧troby. Nowa Pediatria, 2003, 32, 1.
10. Jennet J.C. Falk R.J.: Anti-neutrophil cytoplasmic autoantibodies and associated disease: A review. Am. J. Kidney Dis., 1990, 15, 517.
11. Pietravalle P., Monteleone G., Morano S. i wsp.: Antineutrophil cytoplasmic antibodies are present in long standing type 1 diabetics but do not correlate with selective proteinuria. J. Autoimmun., 1996, 9, 113.
12. Accardo Palumbo A., Triolo G., Giardina E. i wsp.: Detection of anti-myeloperoxidase antibodies in the serum of patients with type 1 diabetes mellitus. Acta Diabetologica, 1996, 33, 103.
13. Eiserich J.P., Baldus S., nan M.L. i wsp.: Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science, 2002, 296, 2391.
14. Heeringa P., Cohen Tervart J.W.: Pathophysiology of ANCA-associated vasculitis: are ANCA really pathogenic? A note of caution. Kidney Int., 2004, 65, 1564.
15. Hansch G.M., Andrassy K.: Pathophysiology of ANCA-associated vasculitis: are ANCA really pathogenic? A note of caution. Kidney Int., 2004, 66, 2090.
16. DCCT Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med., 1993, 329, 977.
17. Baldus S., Heeschen C., Meinertz T. i wsp.: Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation, 2003, 108, 1440.
18. Van Haelst P.L., Asselbergs F.W., van Doormaal J.J. i wsp.: Antineutrophil cytoplasmic antibodies in patients with premature atherosclerosis: prevalence and association with risk factors. J. Int. Med., 2002, 251, 29.
19. Schram M.T., Chatuverdi N., Schalkwijk C. i wsp.: The EURODIAB Prospective Study Group. Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes. Diabetes Care, 2003, 26, 2165.